(LABU) Direxion Daily S&P Biotech - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US25460G1206
LABU: Swap Agreements, Securities, ETFs
The Direxion Daily S&P Biotech Bull 3X Shares (LABU) is an exchange-traded fund (ETF) designed to provide investors with 3X daily leveraged exposure to the S&P Biotechnology Select Industry Index, which tracks the biotechnology sub-industry as defined by the Global Industry Classification Standards (GICS).
The fund achieves its investment objective by investing at least 80% of its net assets in a combination of financial instruments, including swap agreements, securities of the index, and ETFs that track the index. As a non-diversified fund, LABU is more susceptible to volatility and potential losses due to its concentrated investment strategy.
From a technical analysis perspective, LABU is currently trading at $48.32, below its 20-day and 50-day simple moving averages (SMA) of $51.60 and $62.76, respectively, indicating a downtrend. The Average True Range (ATR) of 6.40, representing 13.25% of the current price, suggests high volatility. Given the 52-week high and low of $148.47 and $37.64, respectively, the current price is near the lower end of its recent range.
Fundamentally, LABU has $585.93 million in assets under management (AUM), indicating a moderate level of investor interest. The biotechnology sector, which LABU tracks, is known for its potential for high growth due to ongoing innovation and the development of new treatments and therapies. However, it is also characterized by high risk due to the inherent uncertainties associated with drug development and regulatory approvals.
Forecasting LABUs future performance involves analyzing both its technical and fundamental data. Technically, a break above the resistance level of $62.0 could signal a potential uptrend, while a drop below the support level of $30.0 could indicate further declines. Fundamentally, the growth prospects of the biotechnology sector, driven by advancements in medical research and the demand for new treatments, could support LABUs long-term performance. However, the leveraged nature of LABU means that it is more sensitive to market movements, making it more suitable for short-term trading strategies rather than long-term investments.
Given the current technical downtrend and the high volatility of LABU, a cautious approach is warranted. Investors should closely monitor the funds price movements in relation to its support and resistance levels and be prepared to adjust their strategies accordingly. For those looking to capitalize on short-term movements, LABU could offer opportunities, but it is crucial to manage risk through appropriate position sizing and stop-loss orders.
Additional Sources for LABU ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
LABU ETF Overview
Market Cap in USD | 586m |
Category | Trading--Leveraged Equity |
TER | 0.96% |
IPO / Inception | 2015-05-28 |
LABU ETF Ratings
Growth Rating | -90.4 |
Fundamental | - |
Dividend Rating | 1.0 |
Rel. Strength | -50.1 |
Analysts | - |
Fair Price Momentum | 30.96 USD |
Fair Price DCF | - |
LABU Dividends
Dividend Yield 12m | 0.32% |
Yield on Cost 5y | 0.03% |
Annual Growth 5y | -14.96% |
Payout Consistency | 50.1% |
Payout Ratio | % |
LABU Growth Ratios
Growth Correlation 3m | -15.7% |
Growth Correlation 12m | -85.6% |
Growth Correlation 5y | -87.1% |
CAGR 5y | -42.39% |
CAGR/Max DD 5y | -0.43 |
Sharpe Ratio 12m | 0.48 |
Alpha | -76.48 |
Beta | 2.998 |
Volatility | 86.95% |
Current Volume | 1058.3k |
Average Volume 20d | 1883.2k |
As of June 16, 2025, the stock is trading at USD 58.76 with a total of 1,058,254 shares traded.
Over the past week, the price has changed by -2.73%, over one month by +22.31%, over three months by -26.58% and over the past year by -44.81%.
No, based on ValueRay´s Analyses, Direxion Daily S&P Biotech (NYSE ARCA:LABU) is currently (June 2025) a stock to sell. It has a ValueRay Growth Rating of -90.36 and therefor a clear technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LABU is around 30.96 USD . This means that LABU is currently overvalued and has a potential downside of -47.31%.
Direxion Daily S&P Biotech has no consensus analysts rating.
According to our own proprietary Forecast Model, LABU Direxion Daily S&P Biotech will be worth about 37.2 in June 2026. The stock is currently trading at 58.76. This means that the stock has a potential downside of -36.76%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 37.2 | -36.8% |